Chronic Lymphocytic Lymphoma | Jennifer Woyach, MD


Manage episode 242952773 series 2513286
By Dr Neil Love. Discovered by Player FM and our community — copyright is owned by the publisher, not Player FM, and audio is streamed directly from their servers. Hit the Subscribe button to track updates in Player FM, or paste the feed URL into other podcast apps.

Chronic Lymphocytic Lymphoma, Issue 2, 2019 — Part 2: Our interview with Dr Woyach highlights the following topics as well as cases from her practice:

  • Recent data and evolution of the front-line treatment paradigm for patients with CLL (00:00)
  • Evaluation of MRD and implications for therapy (03:50)
  • Efficacy and tolerability of first-line regimens for CLL (06:14)
  • Perspective on the role of chemoimmunotherapy for patients with CLL (08:41)
  • Case: A woman in her mid-70s experiences a dramatic response after receiving ibrutinib as first-line therapy for CLL (10:48)
  • Bleeding and arthralgias associated with ibrutinib (12:14)
  • Rates of discontinuation and the role of dose reduction to mitigate side effects in patients receiving ibrutinib (14:45)
  • Incidence and management of opportunistic infections during ibrutinib treatment (18:11)
  • Role of chimeric antigen receptor (CAR) T-cell therapy in CLL; effect of ibrutinib on CAR T-cell generation and efficacy (21:54)
  • Case: A man in his late 60s with CLL receives acalabrutinib on a clinical trial after developing atrial fibrillation on ibrutinib therapy (24:01)
  • Therapeutic approach for patients who develop resistance to BTK inhibitors (27:19)
  • Understanding the C481S mutation as a mechanism of resistance to ibrutinib and acalabrutinib (30:47)
  • Targeting the C481S mutation to overcome resistance to BTK inhibitors (32:06)
  • Case: A woman in her mid-60s with del(17p) CLL and no IGHV mutation receives venetoclax after disease progression on multiple lines of therapy (36:11)
  • Prophylactic measures to prevent venetoclax-associated tumor lysis syndrome (38:25)
  • Emerging data with the combination of ibrutinib and venetoclax for CLL (40:04)
  • Activity and tolerability of PI3 kinase inhibitors for patients with CLL (44:17)
  • Acalabrutinib with obinutuzumab for treatment-naïve and relapsed/refractory CLL (47:51)
  • Incidence and spectrum of second cancers among patients with CLL receiving BTK inhibitors (49:51)
  • Case: A man in his early 70s develops RT to DLBCL after receiving ibrutinib as first-line therapy for CLL (51:00)
  • Prognosis and management of RT (53:38)
  • Role of immune checkpoint inhibitors and CAR T-cell therapy in the management of RT (56:37)
  • Ongoing Phase III EA9161 and Alliance A041702 studies evaluating the addition of venetoclax to ibrutinib with obinutuzumab for patients with CLL (59:21)

CME information and select publications

149 episodes